GeneDx Holdings Corp. (WGS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$65.89

From 52W high−60.43%

Volume503626.00

Market cap$1.98B

P/E (TTM)—

P/S (TTM)4.4x

Div yield—

Key dataOct 19, 2026

Open

$65.89

From 52W high

−60.43%

Volume

503626.00

Market cap

$1.98B

ValuationView details →

P/E (Fwd)

76.6x

EV/EBITDA

−26.3x

P/E (TTM)

—

RSI (14)

37.7

MomentumView details →

1D Return

+4.21%

YTD Return

−49.88%

SummaryUpdated Jun 1, 2026

GeneDx Holdings Corp. (NASDAQ:WGS) is a patient-centered health intelligence company founded by Eric Schadt in October 2015 and headquartered in Stamford, Connecticut. The company went public in November 2020 and has established itself as a leader in genetic testing, particularly in pediatric and rare disease genomics. GeneDx operates the Centrellis health intelligence platform, which applies artificial intelligence and machine learning to clinical and genomic data to build comprehensive models of human health and provide personalized medical insights.

Ask drillr about GeneDx Holdings Corp. →

ValuationView details →

P/E (Fwd)

76.6x

P/E (TTM)

—

EV/EBITDA

−26.3x

EV/Sales

4.4x

P/S (TTM)

4.4x

P/B (TTM)

8.1x

ProfitabilityView details →

Gross Margin

68.20%

Net Margin

−23.40%

EBITDA Margin

−16.82%

ROE (TTM)

−43.55%

ROA (TTM)

−22.09%

Asset Turnover

0.92x

GrowthView details →

Revenue YoY

+25.42%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+22.13%

EPS CAGR 3Y

+62.37%

EBITDA YoY

—

MomentumView details →

1D Return

+4.21%

YTD Return

−49.88%

1Y Return

−48.68%

RSI (14)

37.7

vs 50D SMA

−20.04%

vs 200D SMA

−12.71%

Capital & dividendView details →

Debt/Equity

0.69x

Current Ratio

3.30x

Quick Ratio

3.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.01

EPS Surprise

105.32%

Beats (12Q)

8/12

Next Q EPS Est

$0.29

Avg Surprise (4Q)

41.48%

Rev Surprise

3.09%

Financials snapshotView financials →

Revenue (TTM)

454.43M

Net Income (TTM)

−106.36M

Op. CF (TTM)

−48.71M

Next earningsOct 27, 2026 →

Latest newsMore news →

GeneDx Holdings Corp. announced that 27 scientific abstracts had been accepted for the American Society of Human Genetics 2026 Annual Meeting.3h ago

GeneDx introduced Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.17d ago

Similar companies

Progyny, Inc.PGNY Schrödinger, Inc.SDGR Omnicell, Inc.OMCL Sinohealth Technology Holdings Limited02361.HK Certara, Inc.CERT Privia Health Group, Inc.PRVA Find similar companies →

Latest newsMore news →

GeneDx Holdings Corp. announced that 27 scientific abstracts had been accepted for the American Society of Human Genetics 2026 Annual Meeting.3h ago GeneDx introduced Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.17d ago